📅 April 28 | Virtual Webinar
A New Era in Solid Tumor Therapy
CAR T-cell therapy has revolutionized treatment for hematologic malignancies, yet its potential in solid tumors has long been hindered by biological barriers. Tumors create a suppressive microenvironment, and CAR T cells often struggle to expand, persist, and maintain their anti-tumor activity. These challenges have inspired a wave of next-generation innovations designed to unlock the therapy’s full potential.
We are thrilled to invite you to a groundbreaking webinar, delivered in collaboration with the International Conference on Lymphocyte Engineering (ICLE), that explores how CAR T-cell therapy is evolving to overcome these obstacles.
This interactive scientific session will delve into the latest strategies in GPC3-targeted CAR T-cell therapy, examining both pediatric and adult solid tumors and the pioneering research that is shaping future treatment protocols.
What You’ll Learn
- How CAR T-cell therapy is evolving beyond hematologic cancers
- The role of GPC3 targeting in solid tumor treatment
- Breakthrough strategies using cytokine-armored CAR T cells
- How co-expression of IL-15 and IL-21 enhances T-cell fitness, proliferation, and durability
- Real-world insights from leading experts in pediatric oncology and immunotherapy
Speakers
Dr. David Steffin
Associate Chief and Inpatient Medical Director of Pediatric Blood and Marrow Transplantation at Texas Children’s Hospital and Baylor College of Medicine. He specializes in CAR T-cell therapies for pediatric solid tumors, addressing the unique challenges these cancers present. His research has been published widely and informs cutting-edge approaches in immunotherapy.
Moderator
Prof. Dinorah Friedmann-Morvinski
Associate Professor at Tel Aviv University, studies tumor plasticity and the tumor microenvironment in pediatric and adult brain cancers. Her lab develops innovative CAR T-cell and nanomedicine therapies to overcome tumor resistance and improve patient outcomes.